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S U M M A R Y
Objectives: Maraviroc currently represents an important antiretroviral drug for multi-experienced and
viremic HIV patients. This study focused on two main points: (1) determining the prevalence of R5 and
X4 HIV strains in antiretroviral-experienced patients using two main tests currently in use to determine
viral tropism, and (2) the follow-up to 3 years of a limited number of patients who started a new
antiretroviral protocol including maraviroc.
Methods: A group of 56 HIV patients, previously multi-treated, were ﬁrst analyzed by genotyping assay
and TroﬁleTM to establish their eligibility for maraviroc treatment. In addition, 25 subjects selected to
follow a new therapeutic protocol including a CCR5 antagonist were monitored by HIV RNA viral load
and CD4+ cell count.
Results: The determination of viral tropism showed a large percentage of patients with an R5 proﬁle (72%
by genotyping assay and 74% by Troﬁle). The follow-up of most (21 out 25) patients who started the new
antiretroviral protocol showed an undetectable viral load throughout the observation period,
accompanied by a major improvement in CD4 cell count (cells/mm3) (baseline: median CD4 cell count
365, interquartile range (IQR) 204–511; 12 months: median value 501, IQR 349–677, p = 0.042; 24
months: median value 503, IQR 386–678, p = 0.026; 36 months: median value 601, IQR 517–717,
p = 0.001). Among the four non-responder subjects, two showed a lack of drug compliance and two
switched from R5 to X4.
Conclusion: Although our patient cohort was small, the results showed a high prevalence of R5 viral
strains in multi-experienced patients. As well as showing the advantages of genotyping, which can be
performed in plasma samples with low viral load replication, the follow-up of HIV patients selected for
an alternative drug protocol, including a CCR5 antagonist, showed a persistent undetectable viral
replication and a good recovery of CD4 cell count in most treated HIV patients.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The discovery of the two main co-receptors for HIV, CCR5 and
CXCR4, has led to a better understanding of the interaction
between the HIV envelope and host cells,1 and the development of
new therapeutic approaches.2–4 Indeed, the recent introduction of
new molecules, such as CCR5 antagonists able to inhibit viral entry,* Corresponding author. Tel.: +39 051 636 4932; fax: +39 051 307 397.
E-mail address: mariacarla.re@unibo.it (M.C. Re).
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http://dx.doi.org/10.1016/j.ijid.2013.02.020opens new perspectives for HIV patients with previous treatment
failure. Even though early studies5,6 showed that virus isolates
could be divided into phenotypic categories such as non-
syncytium-inducing (NSI) and syncytium-inducing (SI) in the
CD4 T cell line, on the basis of growth capacity and cytopathicity on
peripheral blood mononuclear cells, the difference between NSI
and SI phenotypes was related to a different use of co-receptors.7,8
In particular, NSI viruses predominantly use CCR5, while SI viruses
can use CCR5 and CXCR4 or CXCR4 exclusively.9 However, HIV
tropism has been classiﬁed as R5, X4, or dual/mixed (DM) tropic,
depending on co-receptor use. In particular, the term dual/mixedses. Published by Elsevier Ltd. All rights reserved.
Table 1
Baseline characteristics of HIV patients enrolled in the study
Age, years, median (IQR) 46 (42–52)
Gender, male % 78.5
Risk transmission factors, %
Heterosexual 97
Homosexual 3
IDU 0
CDC stage, % B1, 29; B2, 37; B3, 20; C1, 14
CD4 cell count, cells/mm3, median (IQR) 359 (105–503)
Plasma HIV-1 RNA, copies/ml, median (IQR) 2.4  104 (2.9  103–8.9  104)
Years of ART treatment, median (IQR) 5 (3–10)
IQR, interquartile range; ART, antiretroviral therapy.
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can use either or both chemokine co-receptors, or mixtures of
viruses that exclusively use CCR5 and others that use CXCR4.10
It is well known that CCR5-using viruses predominate after HIV
seroconversion and in the early stages of disease,1,11 whereas
CXCR4 variants appear at later stages and have been associated
with a faster decline in CD4 cell count and hence with disease
progression and a worse prognosis.12–15
Since HIV can change its chemokine receptor usage in 50–60%
of infected subjects during the progression of HIV infection, with
the appearance of dual/mixed viruses,16–18 the inﬂuence of highly
active antiretroviral therapy (HAART) on tropism shift would
certainly help better deﬁne both virus biology and drug treatment.
To this end, some researchers hypothesize that antiretroviral
therapy might exert a different selective pressure on X4 or R5
variants in the viral population, reporting a preferential suppres-
sion of X4 viruses with HAART19–22 and an R5-to-X4 switch in cell
reservoirs with effective therapy.23,24
Growing knowledge on co-receptor usage and the establish-
ment of new antiretroviral drugs able to target viral entry has
increased the number of treatment options and improved the
durability, tolerability, and long-term efﬁcacy of HAART, even
among patients with extensive treatment experience and high
levels of drug resistance.
Among the new drug classes, maraviroc is the ﬁrst and only
CCR5 antagonist approved for the treatment of HIV-infected
patients with a CCR5-tropic infection. However, the use of co-
receptors must now be determined for patients eligible to receive
an anti-CCR5 inhibitor, to exclude CXCR4-using HIV patients.
Tropism is currently established by several techniques devel-
oped over the years, including phenotypic and genotypic methods,
which show varying degrees of correlation in direct comparisons.
Even if a diagnostic gold standard is lacking, the TroﬁleTM assay
(Monogram Biosciences, San Francisco, CA, USA), followed by the
Enhanced Sensitivity Troﬁle Assay, has long been used for the
prospective recruitment of patients in clinical trials.25,26
Recently, genotyping tests (GTT), involving population-based
sequencing of the patient-derived HIV-1 gp120 V3 domain, are
increasingly being used. Moreover genotypic tropism assays have
the great potential for routine assessment of HIV-1 tropism since
they are widely available, relatively inexpensive, and quick to
perform. The OSCAR (Optimizing the Susceptibility to CCR5
Antagonist Response) study, designed to standardize a genotypic
approach, has obtained very good results on a large number of
plasma samples, supporting the routine use of genotyping.27
The present study analyzed a group of 56 HIV-1-infected
HAART-treated patients naı¨ve to maraviroc, who needed to change
their therapeutic protocol due to a high number of drug resistance
mutations and/or persistent levels of viral replication, or adverse
events such as intolerance or non-adherence. The study was
designed to: (1) investigate the prevalence of R5 and X4 HIV strains
in antiretroviral-experienced patients, by genotyping assays
currently in use in our laboratory, and (2) monitor a group of
R5 patients eligible for an antiretroviral regimen including
maraviroc by virological (HIV RNA viral load) and immunological
(CD4+ cell count) evaluation, for up to 3 years after the start of
maraviroc treatment.
2. Materials and methods
2.1. Patients
After giving their informed consent, and in accordance with the
Declaration of Helsinki,28 56 HIV patients naı¨ve to the CCR5
antagonist maraviroc were enrolled in this study, which was
approved by the local ethics committee (Prot.: A4001067 – POEM,Cod. CE: 10029). Patients met the following inclusion criteria: (1)
immunological and/or virological failure under previous antiviral
regimens, or toxicity to current regimen; (2) treatment history (3–
10 years) with a combination of two different nucleoside reverse
transcriptase inhibitors (NRTI) and one non-nucleoside reverse
transcriptase inhibitor (NNRTI), or with two different NRTIs and
one protease inhibitor (PI); (3) availability of co-receptor tropism
assessed at the same time point as plasma collection for V3
sequencing.
Baseline characteristics of the HIV patients are shown in
Table 1. All the subjects were Caucasian; 44 were men and 12 were
women, and they were aged 21–79 years (median age 46 years).
Intensive medical evaluation excluded a history of drug abuse, and
transmission was established to be by sexual contact in all
subjects.
Most patients needed to change their therapeutic protocol as
suggested by a high number of major mutations and/or virological
failure (as conﬁrmed by the lack of a complete viral load
suppression (<20 copies of HIV RNA/ml)) and/or adverse events.
All samples from HIV-1 patients were analyzed for viral load,
CD4 cell counts, and for genotypic and phenotypic determination
of HIV-1 tropism.
2.2. RNA viral load detection and CD4 cell count
All the plasma samples were analyzed for HIV-1 RNA level using
the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (Roche Diag-
nostics GmbH, Mannheim, Germany), in accordance with the
manufacturer’s instructions. HIV RNA levels were expressed as the
number of copies per milliliter of plasma, and the lowest detection
limit of the assay was 20 copies/ml. Plasma samples were
separated from the cell fraction by centrifugation at 700  g for
10 min and then frozen at 70 8C until tested for HIV-1 RNA.
Peripheral blood CD4 lymphocytes were counted by ﬂow
cytometry (FACScan; Becton and Dickinson, Mountain View, CA,
USA) using a commercially available monoclonal antibody
(Becton-Dickinson), as previously described.29
2.3. Prediction of HIV tropism
HIV co-receptor tropism was determined by genotypic based
population sequencing and/or Enhanced Sensitivity Troﬁle Assay
(ESTA) (Monogram Biosciences).
Genotypic estimation of co-receptor usage was carried out in
plasma specimens collected at enrollment and throughout the
observation period. Brieﬂy, RNA was prepared from 1 ml plasma in
an automated platform using an EasyMag instrument (bioMe´rieux,
Marcy l’Etoile, France). Elution was performed in 60 ml. In addition,
to exclude the presence of contaminating DNA, isolated RNAs from
samples with a low level of viral replication were treated with
DNAse (Roche) and both PCR and sequencing were performed in
triplicate.
Table 2
CD4 cell count and RNA viral load in HIV patients
Patient RNA viral load/ml CD4 T cells/ml
1 69 476
2 93 365
3 127 428
4 353 422
5 500 358
6 780 472
7 1100 605
8 1200 360
9 1300 538
10 2000 586
11 2100 814
12 2500 328
13 2800 538
14 2900 460
15 3100 89
16 3200 322
17 3700 697
18 4800 297
19 6900 346
20 7400 815
21 8200 361
22 11 000 374
23 11 000 373
24 13 000 503
25 14 000 519
26 16 000 962
27 18 000 503
28 19 000 98
29 30 000 25
30 30 000 253
31 32 000 577
32 32 000 436
33 34 000 213
34 39 000 10
35 41 000 26
36 43 000 754
37 44 000 390
38 57 000 403
39 64 000 289
40 71 000 214
41 78 000 653
42 79 000 295
43 93 000 628
44 97 000 18
45 120 000 60
46 140 000 148
47 150 000 195
48 190 000 29
49 240 000 259
50 247 000 128
51 260 000 30
52 340 000 23
53 440 000 22
54 500 000 22
55 500 000 15
56 500 000 12
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RNA, and the cDNA product was used to amplify a region of 680
nucleotides spanning the V3 env region using the forward primer
V3S2 50CAGCACAGTACAATGTACACA 30 (nt 630–650) and reverse
primer V3AS5 50CTTCTCCAATTGTCCCTCA 30 (nt 1292–1310) with a
commercial one-step RT-PCR kit (Superscript with the high ﬁdelity
proof-reading platinum Taq DNA polymerase, Invitrogen by Life
Technologies Corp.). RT-PCR was performed with the following
thermal proﬁle: 120 s at 90 8C, 20 min at 50 8C, and 2 min at 94 8C,
followed by 40 cycles with 30 s at 94 8C, 30 s at 57 8C, and 120 s at
68 8C, and a ﬁnal extension for 7 min at 68 8C.
A 35-amino acid region (V3 loop) was directly sequenced with
Thermo Sequenase Enzyme from PCR products in both directions
(TruGene Core Reagent Open Kit, Siemens Healthcare Diagnostics
Inc., Tarrytown, NY, USA) using CyTM5.5/CyTM5.0 Dye Primer V3S6
(50-CTGTTAAATGGCAGTCTAGC-30) and V3AS3bis (50-
CAATTTCTGCCCCTC GGT-30) (3 mM), respectively.
The speciﬁc cycling program was 5 min at 94 8C, followed by 30
cycles of 20 s at 94 8C, 20 s at 55 8C, and 60 s 70 8C, and a ﬁnal
extension for 7 min at 70 8C. After 3 min of denaturation,
fragments were separated on a TruGene Tower (Siemens
Healthcare Diagnostics Inc.) with a 6% polyacrylamide gel.
Electropherogram data were analyzed using the OpenGene
automated DNA sequencing system and V3 consensus B sequence
as reference.
The V3 sequences generated were then interpreted using a
bioinformatics-driven prediction system, freely available on the
web: geno2pheno[coreceptor] (http://coreceptor.bioinf. mpi-
inf.mpg.de/index.php).
Nucleoside sequence tropism prediction was performed using
Geno2pheno[coreceptor] with a false-positive rate (FPR) of 10%, in
accordance with the current European guidelines.10,30
The Troﬁle assay classiﬁes HIV isolates as R5-tropic, X4-tropic,
or DM (indicating dual and/or mixed-tropic virus) based on
conﬁrmation of decreased relative light units (RLU) by 50% or more
upon addition of speciﬁc co-receptor inhibitors.
2.4. The genotypic susceptibility score (GSS) of HIV patients enrolled in
the new protocol including maraviroc
The genotypic susceptibility score (GSS) of the optimized
background regimen (OBT) was calculated (using the Stanford
University HIV DB genotypic resistance interpretation algorithm)
and the corresponding levels of resistance for each drug in the
regimen (maraviroc excluded) were scored as follows: susceptible
and potential low-level resistance = 1; low and intermediate-level
resistance = 0.5; high-level resistance = 0.
2.5. HIV-1 subtyping
HIV-1 subtyping was conducted by phylogenetic analysis using
a neighbor-joining method with the Kimura 2-parameter distances
(DNADIST and NEIGHBOUR modules of the PHYLIP software;
http://evolution.genetics.washington.edu/phylip.html). All pol
sequences, available for each sample, were used for alignment
with reference strains of a known subtype derived from the Los
Alamos database (http://www.hiv.lanl.gov) using ClustalX and
edited manually by BioEdit.
2.6. Statistical analysis
Differences between R5-tropic and non-R5-tropic groups were
calculated using the Mann–Whitney non-parametric test. Differ-
ences between enrolment and follow-up in the R5 group were
analyzed by Wilcoxon non-parametric test. All tests were two-
tailed, with only p-values of <0.05 considered to be signiﬁcant. Allstatistical analyses were performed using SPSS v20.0 software
(IBM Corp., released 2011; IBM SPSS Statistics for Windows,
Armonk, NY, USA).
3. Results
We selected a group of 56 patients previously treated with a
combination of two different NRTIs and one NNRTI, or by two
different NRTIs and one PI. All these patients needed a therapeutic
protocol modiﬁcation and had never been treated with maraviroc.
They were analyzed for viral load, CD4 cell counts, and for
genotypic (time 0 and afterwards) and phenotypic (time 0)
determination of HIV-1 tropism.
Figure 1. Percentage of viral strains in multi-treated patients with different tropism
proﬁles assessed by genotyping sequencing (dark) and Troﬁle assay (light). Figure 2. HIV strains characterized by genotyping sequencing (y-axis) and Troﬁle
assay (x-axis).
Table 3
HIV patients enrolled in the study with different results obtained by Troﬁle and
genotyping test
Patient Troﬁle Genotyping test (FPR 10%)
14 R5 X4 (0.1%)
53 R5 X4 (3.9%)
45 X4 R5 (13.2%)
7 D/M X4 (7.4%)
17 D/M X4 (4.2%)
18 D/M X4 (7.6%)
21 D/M X4 (8.5%)
29 D/M X4 (2.7%)
33 D/M X4 (0.1%)
35 D/M X4 (1.7%)
46 D/M X4 (0.2%)
54 D/M X4 (0.2%)
55 D/M X4 (0.2%)
FPR, false-positive rate; R5, R5-tropic virus; X4, X4-tropic virus; D/M, dual mixed
virus.
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The subjects enrolled in the study were characterized by
variable levels of HIV replication (Table 2). In particular, six
subjects (patients 1–6) had a low viral load (ranging from 69 to 780
HIV copies/ml), 15 subjects (patients 7–21) had a viral replication
ranging from 1.1  103 to 8.2  103 copies/ml (median value
2.9  103, interquartile range (IQR) 2  103–4.8  103), and 35 had
a high viral load, ranging from 1.1  104 to >5.0  105 HIV RNA
copies/ml (median value 6.4  104, IQR 3  104–1.9  105). CD4+
cell counts, ranging from 10 to 962 cells/mm3, were signiﬁcantly
different (p = 0.003) only in the two groups of patients with
medium and high viral loads (538, IQR 328–697 vs. 214, IQR
26–436).
3.2. Tropism assays by genotypic sequencing and Troﬁle assay
All 56 viral sequences, extracted from plasma samples, were
typed by genotypic based population sequencing. The Troﬁle assay
was performed on only 50 viral strains, for which the viral load was
>1000 copies/ml.
In particular, six of the 56 patients (patients 1–6 in Table 2)
characterized by a low number of HIV RNA copies/ml (median
value 240 HIV RNA copies/ml, IQR 87–570), were only analyzed by
genotypic test in triplicate; this showed R5-tropic virus in four
patients and X4 variants in two patients, setting the FPR at 10%.
Paired genotypic/phenotypic results in plasma samples were
successfully obtained for 50 patients. The ESTA identiﬁed R5-tropic
virus in 37 out of 50 samples (74%) and X4- and DM-tropic viruses
in 13 samples (26%). A high prevalence (36 out of 50 samples; 72%)
of R5 variants was also detected by GTT (Figure 1); 28% of viral
strains (14 out 50 samples) displayed an X4-using co-receptor. Due
to the performance of the genotyping test, DM strains were
disclosed only by Troﬁle assay in 10 HIV patients (20%).
3.3. Tropism characteristics, RNA viral load, and CD cell count
We found a high prevalence (more than 70%) of R5 strains in our
highly treatment-experienced subjects. Focusing on genotypic test
results, available for all patients enrolled in the study, 40 of 56
subjects had a virus that used only CCR5 and 16 of 56 had a virus
that used CXCR4, without signiﬁcant differences in HIV RNA load in
R5-infected subjects (median value 1.8  104) vs. X4-infected
subjects (mean median value 3.4  104) (p = 0.935), and/or CD4
levels (374 vs. 213 in R5- and X4-infected subjects, respectively;
p = 0.204).Moreover, on stratifying our patients on the basis of different
amounts of HIV RNA, X4-tropic viruses were distributed without
any correlation in low, intermediate, and high viral loads,
respectively (p = 0.064, 0.289, and 0.163, respectively). No
signiﬁcantly different results were obtained when stratifying
our patients on the basis of CD4 cell count results (p = 0.598, 0.138,
and 0.569 in patients with CD4 levels ranging from 0 to 350, 351 to
550, and >551 cells/mm3, respectively).
3.4. Tropism characteristics and length of antiretroviral treatment
The mean duration of previous antiretroviral therapy was quite
similar (p = 0.684) in patients harboring non-R5 virus (median
value 5, IQR 4–6) and patients harboring R5 virus (median value 5,
IQR 4–6.7).
3.5. Matched and unmatched results
As shown in Figure 2, R5 strains were detected in 35 samples
and X4-tropic viruses in two samples, irrespective of the assay
used in this study.
Unmatched results were only observed for three specimens: in
particular, two viral strains (samples from patients 14 and 53,
Table 3) were characterized as R5 by Troﬁle and X4 by genotypic
test, and one viral strain (sample from patient 45, Table 3) as X4 by
Troﬁle and as R5 by genotypic test (Table 3). Even if the nature of
Table 4
Genotypic susceptibility scores (GSS) calculated before starting the new therapeutic
protocol including maraviroc and the optimized background regimen (OBT)
Patient OBT GSSa
1 TDF +FTC+RAL+DRV/r 2.5
2 TDF +FTC+RAL+DRV/r 2.5
4 RAL+DRV/r 2
8 RAL+DRV/r 2
11 FTC+TDF+DRV/r 1
13 RAL+DRV/r 2
23 3TC+RAL+DRV/r 2
24 RAL+DRV/r 2
25 RAL+DRV/r 2
26 RAL+DRV/r 2
27 RAL+DRV/r 1
30 3TC+ABC+RAL+ETV 3
31 RAL+ETV 1.5
34 3TC+TDF+RAL+ETV 1
36 FTC+TDF+DRV/r 2
37 FTC+TDF+RAL 2
39 3TC+RAL+ETV 2
40 ETV+DRV/r 1
42 FTC+TDF+DRV/r 1.5
44 3TC+RAL+DRV/r 1.5
47 RAL+DRV/r 2
49 RAL+DRV/r 2
51 FTC+TDF+RAL+ETV 1.5
52 3TC+ABC+RAL 2.5
56 3TC+RAL+DRV/r 1.5
ABC, abacavir; DRV/r, darunavir/ritonavir; ETV, etravirine; FTC, emtricitabine; RAL,
raltegravir; TDF, tenofovir; 3TC, lamivudine.
a The values in the last column represent the sum of the single score (susceptible
and potential low-level resistance = 1; low and intermediate-level resistance = 0.5;
high-level resistance = 0) for each drug in the OBT (excluding maraviroc).
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acceptable comparison, the detection of dual/mixed-tropic viral
strains merits separate comment. All 10 samples classiﬁed as DM
by Troﬁle, showed a non-R5 proﬁle by genotyping test with an FPR
ranging from 0.2 to 8.5, as shown in Table 3. In particular, the low
value of FPR detected in at least six samples seemed to be strictly
correlated to an X4-tropic virus, or at least to an X4 virus, largely
predominant in a DM population.
3.6. Phylogenetic analysis
Phylogenetic analysis of the HIV-1 pol gene Reverse Transcriptase
(RT) and Protease (PR) sequences ampliﬁed directly from plasma
revealed that 52 patients (93%) were infected with subtype B virus.
In four cases (7%), non-B variants included F1 (R5-tropic) clade
variant, CRF 02Ag (R5-tropic), BF1 (X4), and C (X4), respectively.
3.7. Viral tropism, OBT, GSS, and the follow-up of eligible patients
Among the patients enrolled in our study, 25 HIV patients
harboring an R5 viral strain at genotyping analysis gave their
informed consent to start a new therapeutic protocol including
maraviroc. In particular, an OBT including maraviroc plus an
integrase inhibitor (raltegravir) associated with an RT inhibitor
(tenofovir/emtricitabine or lamivudine) or a protease inhibitor
(darunavir + ritonavir) were selected on the basis of treatment
history and viral resistance testing at the time of tropism screening
(Table 4). Results on the GSS of the OBT showed a median GSS value
in the entire group of 1.84 (IQR 1.5–2), with a median value 2.0.
None of patients enrolled in the study showed a GSS suggestive of
virologic failure.
As shown in Table 5, the median HIV RNA viral load value at
baseline was 3.2  104 copies/ml (ranging from 69 to 5  105) and
the median CD4 cell count value was 365 cells/mm3 (ranging from
10 to 962) (Table 5).The follow-up of these patients at 12, 24, and 36 months after
starting the new antiretroviral protocol showed a complete drop
in HIV RNA viral load (<20 HIV RNA/ml) persisting throughout
the observation period in 21 (84%) patients at 12 months. These
patients were also characterized by a good recovery of CD4
from the ﬁrst control. In particular, a major and signiﬁcant
increase in CD4 cell count was observed from time 0 (median
CD4 cell count 365, IQR 204–511) onwards (12 months: median
value 501, IQR 349–677, p = 0.042; 24 months: median value
503, IQR 386–678, p = 0.026; 36 months: median value 601, IQR
517–717, p = 0.001).
Among the non-responder subjects, two patients (patients 34
and 52, Table 5) showed a switch to X4-tropic virus at 12 and 24
months, respectively, after starting therapy. In particular, despite
the persistence of viral replication (1000 copies/ml throughout the
observation period), patient 34 showed an optimal recovery of CD4
cell count, showing a clear-cut increase in CD4 from 10 cells/ml to
433 cells/ml at 12 months, up to 608 cells/ml at 36 months. Despite
virological and immunological success documented at 12 months,
patient 52 later showed a progressive decline in CD4 cell count and
a virological rebound corresponding to the emergence of an X4
variant.
Patients 30 and 51 showed very high levels of viral replication
throughout the observation period, even if patient 30 showed a
slight increase in CD4 cell count.
None of these failing patients showed a lower GSS value that
could be associated with treatment failure.
4. Discussion
Maraviroc has been approved for HIV-infected patients
harboring R5-tropic viruses and is recommended for the treatment
of antiretroviral-experienced patients failing prior regimens. The
favorable pharmacokinetic properties and the good safety proﬁle
of this drug further support its consideration as part of switch or
simpliﬁcation strategies in antiretroviral-treated patients with
virological failure. Several phenotypic and genotypic tests have
been developed to determine viral tropism. The Troﬁle assay is
most often used, even though the turnaround time, high costs,
sample transport logistics, and its application only in plasma
samples with HIV RNA 1000 copies/ml could represent major
limitations. Since the determination of HIV tropism is crucial to
assess an antiretroviral regimen including maraviroc and is
essential for clinical use, genotypic population sequencing, a
trouble-free alternative to the Troﬁle assay, is considered the
preferred method in Europe.30 Genotypic tests analyse the
sequence of the HIV envelope gp120 variable loop (V3), the main
determinant of co-receptor usage and the generated V3 sequences,
and are interpreted using algorithms such as Geno2Pheno and
position-speciﬁc scoring matrices (PSSMX4R5). In addition, these
tests have the great advantage of being applicable to plasma
samples with viral replication levels <1000 HIV RNA copies and to
peripheral blood mononuclear cell (PBMC) samples.27,31 On the
other hand, the ESTA showed a high sensitivity level with a
certiﬁed capacity of detecting a 0.03% minority variant.32–34 A
number of clinical studies have reported high performances of
genotypic HIV-1 tropism testing in clinical practice in several
European countries using the enhanced sensitivity version of
Troﬁle (ESTA) as the reference assay.35–37
As maraviroc currently represents an important antiretroviral
drug for multi-experienced and viremic HIV patients, our study
focused on two main points: an evaluation of the prevalence of
viruses with different tropism in long-standing experienced
patients, and the follow-up of a selected group of patients
characterized by an R5 viral strain, who started a new antiretrovi-
ral protocol including maraviroc.
Table 5
Results obtained by Troﬁle and genotyping test in HIV patients, characterized by CD4 cell count (CD4T cells/ml) and RNA viral load at enrollment and during the 3-year follow-
up
Patient Genotyping test Troﬁle CD4 T cells/ml RNA viral load, copies/ml
At enrollment 12 months 24 months 36 months At enrollment 12 months 24 months 36 months
1 R5 ND 476 501 453 593 69 <20 <20 <20
2 R5 ND 365 303 441 511 93 <20 <20 <20
4 R5 ND 422 536 525 535 353 <20 <20 <20
8 R5 R5 360 532 489 594 1200 <20 <20 <20
11 R5 R5 814 1000 1092 1139 2100 <20 <20 <20
13 R5 R5 538 669 739 719 2800 <20 <20 <20
23 R5 R5 373 536 672 827 11 000 <20 <20 <20
24 R5 R5 503 576 728 711 13 000 <20 <20 <20
25 R5 R5 519 496 684 711 14 000 <20 <20 <20
26 R5 R5 962 349 508 633 16 000 <20 <20 <20
27 R5 R5 503 560 378 451 18 000 <20 <20 <20
30 R5 R5 253 420 285 326 30 000 6000 20 000 100 000
31 R5 R5 577 756 1000 1159 32 000 <20 <20 <20
34 R5 R5 10 433 600 608 39 000 1000 1000 1000
36 R5 R5 754 912 427 583 43 000 <20 <20 <20
37 R5 R5 390 686 713 754 44 000 <20 50 50
39 R5 R5 289 346 395 439 64 000 <20 <20 <20
40 R5 R5 214 320 348 620 71 000 <20 <20 <20
42 R5 R5 295 733 560 592 79 000 <20 <20 <20
44 R5 R5 18 388 451 587 97 000 <20 <20 <20
47 R5 R5 195 734 664 787 150 000 <20 <20 <20
49 R5 R5 259 468 503 651 240 000 <20 <20 <20
51 R5 R5 30 21 34 ND 260 000 190 000 100 000 10 000
52 R5 R5 23 350 327 172 340 000 <20 10 000 10 000
56 R5 R5 12 86 129 241 500 000 <20 <20 <20
ND, not detectable; R5, R5-tropic virus.
I. Bon et al. / International Journal of Infectious Diseases 17 (2013) e875–e882e880Fifty-six previously multi-treated HIV patients were selected.
These patients needed to change their therapeutic protocol due to
a high number of major mutations, or high levels of viral
replication, or adverse events (such as intolerance and non-
adherence). The outcome of the determination of viral tropism,
the ﬁrst step prior to the use of CCR5 antagonists, showed a good
percentage of samples with an R5 proﬁle, suggesting the
suitability of maraviroc in multi-treated patients and an accept-
able concordance between the two tests performed. However,
several literature reports found a greater overall prevalence of X4
viruses in experienced patient cohorts compared to naı¨ve
patients.38–42 In addition, in our experimental conditions, the
presence of X4- or R5-tropic virus seemed to be independent of
the length of previous antiretroviral treatment, different levels of
RNA replication, and CD4 cell count.
Interestingly six viral strains from HIV-1 patients with a low
viral load could only be characterized by genotyping test due to a
limitation of the Troﬁle assay, which can only be applied to
samples with a viral load 1000 HIV RNA copies/ml; V3
sequencing is characterized by a high rate of efﬁciency even
when viremia is low.27,43–45
Our data emphasize the peculiarity of genotype testing that is
also able to characterize viral strains from HIV subjects with low
but detectable levels of HIV replication despite previous long-
lasting antiretroviral therapy. In addition, among the six patients
not evaluable by Troﬁle, three were further included in the
maraviroc protocol, showing a clear-cut drop in viral replication
maintained throughout the observation period (from 12 to 36
months).
Concerning unmatched results, discordant data (X4 by geno-
typing test and R5 by Troﬁle) in two patients may suggest the need
to sequence more extended viral regions, both including the largest
V3 and also the V1 and/or V2 loop, to better deﬁne the co-receptor
use of viral strains.27,46 Even if the clinical relevance of including
additional regions has yet to be established, previous studies
have demonstrated that mutations in the V1/V2 loops and the C4
region of the gp120 are involved in the mechanisms underlyingco-receptor binding and usage.47,48 The opposite situation (R5 by
genotyping test and X4 by Troﬁle) occurred in only one case.
Phylogenetic analysis demonstrated that this patient was infected
by a subtype C, so the test result might be related to the Troﬁle
algorithm, developed, standardized, and constructed mostly from
subtype B V3 clones. The performance with non-B subtypes is
expected to be lower, ranging from 17% to 67%, in HIV patients
infected with non-B subtypes, despite some discrepancies in
published reports.26,27,49,50
Finally, dual/mixed-tropic HIV-1 strains were found in 10 of 50
patients. Mixtures of viruses with different V3 sequences could
lead to a poor sequence quality, impacting on the interpretation of
bioinformatic tools.51 Dual-tropic strains represent a complex
virus family using CCR5 and CXCR4 at greatly variable levels.51–53
Geno2pheno FPR have been correlated with the preferential use of
CCR5 or CXCR4 of dual tropic strains.54 Since the nature of the two
tests employed differs, we could not consider the 10 samples
classiﬁed as having X4-tropic virus by genotypic test and DM by
Troﬁle to be discordant. However, a correct interpretation of the
results obtained may be crucial. In this regard, genotypic testing
has the major advantage of offering results graded as FPR, that can
be adapted to the patient’s needs, whereas Troﬁle results are
simply R5 or X4 or DM reports, without access to the raw data.55,56
A correct reading of genotyping results focused on FPR could offer
several advantages for clinical use.
Although European guidelines30 suggest setting the FPR at 10%,
FPR settings from 2% to 10% could account for different tropism
interpretations.56 Under our experimental conditions, setting the
FPR at 2%, at least ﬁve viral sequences (patients 7, 17, 18, 21, and
29, Table 2), classiﬁed as X4 by genotyping test (FPR set at 10%),
could be differently coded and considered HIV strains with a mixed
presence of X4 and R5 viral strains, opening new therapeutic
possibilities for these patients.54,57
Interestingly, several studies17,52,53,57 have disclosed a consid-
erable fraction of dual viruses preferentially able to infect either
CCR5 or CXCR4 target cells in vivo, with obvious clinical
implications.
I. Bon et al. / International Journal of Infectious Diseases 17 (2013) e875–e882 e881The second aim of our study was the follow-up of a selected
group of patients who started a new antiretroviral protocol
including maraviroc plus OBT. It has been repeatedly shown that
potent and fully active drugs in the background regimen have an
additional beneﬁcial effect when therapy with maraviroc is
initiated,58 since it is associated with signiﬁcantly greater virologic
and immunologic efﬁcacy.59–61 Interestingly, most of our patients
showed a marked improvement in CD4 cell counts accompanied by
an undetectable viral load persisting throughout the observation
period. Focusing our attention on the three patients who started
the new therapeutic protocol based only on genotyping test,
optimal results for both CD4 cell count (conﬁrming maraviroc as an
optimal immunomodulant drug) and a persistently undetectable
viral load were observed, emphasizing a better availability of this
test and the great limitation of Troﬁle in samples with low viral
loads.
Those patients who did not show an appropriate response to the
CCR5 inhibitor merit separate comment. In-depth clinical analysis
of these patients showed a lack of compliance in at least two
subjects (patients 30 and 51), also certiﬁed by a dramatic drop in
CD4 cell count, most evident in one of the patients (patient 51). A
switch from R5 to X4 was observed in the other two non-responder
patients. A constant contained level of HIV replication was
observed in at least one subject, who also presented a good level
of CD4+ lymphocytes, whereas the X4 replacement completely
justiﬁed the increasing viral load and drop in CD4 cells in the other
patient.
Treatment failure in these patients could not have been
associated with a lower GSS value, because none of the four failed
patients showed medium or high levels of resistance.
In conclusion, besides highlighting the great merit of the
genotyping test,10 our 3-year follow-up study showed the
virological and immunological beneﬁt of maraviroc in the
treatment of patients with advanced R5 HIV-1 infection. Since
HIV tropism and its modiﬁcations during the course of infection
may strongly inﬂuence treatment options, the straightforward
monitoring of patients treated with salvage regimens is a strategic
choice in a new era of antiretroviral treatment.
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